Review

Drug-drug cocrystals: Opportunities and challenges

Xiaojuan Wang, Shuzhang Du, Rui Zhang, Xuedong Jia, Ting Yang, Xiaojian Zhang*
Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

ARTICLE INFO

Article history:
Received 8 April 2020
Revised 11 June 2020
Accepted 16 June 2020
Available online 9 July 2020

ABSTRACT

Recently, drug-drug cocrystal attracts more and more attention. It offers a low risk, low-cost but high reward route to new and better medicines and could improve the physiochemical and biopharmaceutical properties of a medicine by addition of a suitable therapeutically effective component without any chemical modification. Having so many advantages, to date, the reported drug-drug cocrystals are rare. Here we review the drug-drug cocrystals that reported in last decade and shed light on the opportunities and challenges for the development of drug-drug cocrystals.

© 2020 Shenyang Pharmaceutical University. Published by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

At the cellular and organ levels, complex diseases such as cancer, diabetes, infectious diseases, and cardiovascular diseases are associated with multiple alterations in molecular pathways and complex interactions [1]. When considering drug treatment strategies in these complex diseases, single-target mono-therapy approaches have fundamental limitations as the disease phenotypes are rarely driven by single molecular entities. In addition, while there may be benefits from using a single compound in the treatment of a disease, treatments consisting of mixtures of active pharmaceutical ingredients (APIs) often have superior effects [2]. Consequently, the combination of multiple APIs into unit doses has become a popular drug development strategy. The use of multiple-targeting fixed dose drug combinations (FDCs) can help reduce pill load without the additional risk of adverse events or drug resistance [3]. As a result, FDCs could simplify dosage regimens (e.g., reduce the number and timing of dosage units the patient must take) and improve patient compliance [4], particularly among the patient populations with special needs such as geriatric and pediatric patients [5]. In addition, these FDCs are being used to achieve highly specific drug-delivery profiles and targeted release to specific sites within the body, and extend product life cycles. However, the development of FDC remains a major challenge in drug development because of its various disadvantages, such as stability, solubility differences and incompatibility between the parent drugs [6]. Among the common FDC formulation designs, the bilayer tablet has many advantages over the monolithic tablet, such as avoiding the problem of chemical stability between two incompatible drugs, providing both a rapid release layer and a slow release layer to produce the

* Corresponding author.
E-mail address: zhangxj_0524@163.com (X.J. Zhang).
Peer review under responsibility of Shenyang Pharmaceutical University.

https://doi.org/10.1016/j.ajps.2020.06.004
1818-0876/© 2020 Shenyang Pharmaceutical University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
desired overall drug release kinetics for optimal therapeutic outcome [3–4,7]. However, the successful development of bilayer tablet products must also overcome new challenges in formulation design, manufacturing process control, and product performance requirements unseen in traditional monolithic tablets. Therefore, it is necessary to develop new technologies to overcome these problems. Drug-drug cocrystal (DDC) is one of the most suitable methods.

According to the FDA, co-crystals are defined as ‘dissociable multicomponent solid crystalline supramolecular complexes composed of two or more components within the same crystal lattice where in the components are in neutral state and interact via nonionic interactions.’ [8] In the past decade, pharmaceutical co-crystals have been designed as a new solid form by virtue their capability to modulate physicochemical properties of APIs. Since several key publications [7,9–10] in 2003–2004 demonstrated that cocrystallization could be applied to improve the physicochemical properties of drug substances, the researches of cocrystals related to pharmaceutical science have been grown rapidly. Nair et al. developed a cocrystal of posaconazole-4-aminobenzoic acid with superior solubility and dissolution behavior [11]. Das et al. prepared a cocrystal of moxifloxacin with trans-cinnamic acid improved residence time in the lungs [12]. Chen et al. reported a cocrystal of temozolomide and baicalein with modulated plasma drug concentration [13]. Mei et al. synthesized a cocrystal of nifdefipine and isonicotinamide with superior photostability [14]. In addition, several drugs are marketed as a cocrystal, for instance, irapragliflozin-L-proline [15], eglinde-L-pyroglutamic acid [16], escitalopram-oxalate [17] and chloral-betaine [18] cocrystals.

While both components of a cocrystal are APIs, the cocrystal could be called DDC [19]. DDC represents a viable approach to overcome the problems associated with traditional combination drugs. It can also modulate physicochemical properties of parent drugs and can be used as potential solid forms for the delivery of dual drugs therapy. Compared to other drug combination technologies, DDC may improve the physicochemical properties of relevant APIs, such as improved dissolution property of at least one component, increased bioavailability, enhanced stability of unstable components and assistance in lifecycle management of existing products. Carmen Almansa et al. reported a cocrystal of tramadol hydrochloride and celecoxib (CTC) in 2017 [20]. The dissolution studies showed that the intrinsic dissolution rate (IDR) of celecoxib was increased and that of tramadol hydrochloride is released slower. Such IDR result was subsequently correlated with a positively modified clinical pharmacokinetic profile in comparison with commercially available single-entity reference products and the open combination [21]. In humans, Tramadol was absorbed more slowly from CTC, resulting in a reduction in peak plasma concentration (C_{max}), while celecoxib was absorbed faster from CTC. In addition, the phase II clinical studies showed that CTC also presented a superior analgesic effect compared to tramadol and celecoxib for the management of moderate to severe pain following extraction of two or more impacted third molars requiring bone removal [22]. This DDC also got new intellectual property protection and may prolong the lifecycle of both celecoxib and tramadol. Zaworotko et al. developed a DDC of meloxicam with aspirin [23]. This DDC presented a 44-fold increase in pH 7.4 phosphate buffer solubility and a fourfold improved bioavailability. Lu et al. reported a DDC synthesized by nicotinamide with tranilast [24] and reported a 1.9 times higher solubility and improved photostability compared to those of pure tranilast. Compared to general cocrystals, DDCs could offer potential advantages of synergistic and/or additive effects and sometimes they may extend their useful range to treat new diseases. Zegarac et al. developed a DDC of sildenafil and aspirin with improved IDR compared with a marketed sildenafil citrate salt [25]. The DDC also displays a potential application in the treatment of erectile dysfunction in patients with cardiovascular complications.

Although more and more pharmaceutical cocrystals had been developed, there is limited published work available on DDCs. Here we review the DDCs that reported in last decade and shed light on the opportunities and challenges for the development of DDCs.

### 2. Reported DDCs in the last decade

Recently, several DDCs formed with the APIs in a variety of therapeutic areas have been reported. Among them, the nonsteroidal antiinflammatory drugs (NSAIDs) formed the most multi-drug cocrystals and approximate half of the reported DDCs have at least one NSAID as their cocrystal co-former. The antitubercular and diuretic APIs formed the second and third most DDCs, more than one third of the reported DDCs are formed with at least one of these two types of APIs.

#### 2.1. DDCs of NSAIDs

NSAIDs are the most common and effective drugs used to relieve pain of the patients suffering from arthritis, low back pain and soft tissue pain. These drugs work by blocking the class of the enzymes called cyclooxygenases (COX) and subsequently the production of prostaglandins. Table 1 listed the DDCs of NSAIDs reported in the last decade. Among the 30 reported DDCs, 7 DDCs were formed with two NSAIDs and the other 23 DDCs were formed with one NSAID and one other API. The pharmaceutical properties of 12 DDCs had not been evaluated. The other 18 DDCs exhibited various pharmaceutical enhancements. 14 DDCs presented improved dissolution properties, 3 DDCs showed enhanced stability, 3 DDCs exhibited improved drug release and 1 DDC displayed an improved in vivo stability. Nangia and his team reported a 1:1 DDC of androgapholide and salicylic acid [26]. This DDC presented 12 times higher solubility, 3 times faster IDR and relatively 2 times higher estimated drug release. In addition, the androgapholide–salicylic acid cocrystal completely inhibited the chemical transformation of androgapholide to its inactive sulfate metabolite. Zhang et al. developed a DDC of piroxicam and clonixin [27]. Both of the two elements are NSAIDs. 8 solvates of this DDC were obtained and the pharmaceutically acceptable ethyl acetate solvate demonstrated superior physical stability.
against hydration. Surov et al. developed 2 DDCs of diflunisal and diclofenac with theophylline [28]. The IDR of diclofenac-theophylline was around 1.2 times higher than for each drug alone. Enhanced hygroscopic stability of theophylline was observed at 100% relative humidity (RH) (Scheme 1–4).

2.2. DDCs of antitubercular drugs

Tuberculosis is a chronic infectious disease caused by mycobacterium tuberculosis and antitubercular drugs are used to treat tuberculosis. Table 2 listed the DDCs of antitubercular drugs reported in the last decade. Among the 13 reported DDCs, the pharmaceutical properties of 3 DDCs had not been evaluated. The other 10 DDCs exhibited various pharmaceutical enhancements. 8 DDCs presented improved dissolution properties, 4 DDCs showed optimized diffusion permeability and 1 DDC exhibited enhanced hydration stability. Chieriotti et al. developed a DDC of ethionamide with salicylic acid and reported an increased dissolution rate compared to the pure ethionamide [29]. Ellena et al. reported a 1:1 DDC of 5-fluorocytosine with isoniazid [30]. The DDC has superior phase stability properties against moisture when compared to the starting pharmaceutical ingredients. Yan et al. developed a drug-bridge-drug ternary cocrystal of isoniazid with fumaric acid and pyrazinamide [31]. This cocrystal exhibits optimized formulation capacity and in vitro/vivo synergistic effects, which provides a new insight into antituberculosis combination drugs.

2.3. DDCs of diuretic drugs

Diuretics are used as the sole therapeutic agents to treat hypertension. Diuretics can also be used in combination with other antihypertensive drugs to treat more severe forms of hypertension. Table 3 listed the DDCs of diuretic drugs reported in the last decade. Among the 9 reported DDCs, the pharmaceutical properties of 3 DDCs had not been evaluated. The other 6 DDCs all presented improved dissolution properties. In addition, 4 DDCs also showed optimized diffusion permeability. Desiraju et al. developed a DDC formed by hydrochlorothiazide and nicotinamide [32], and the DDC have higher solubility (1.3 fold) and

Table 1 – DDCs of NSAIDs reported in the last decade.

| Drug combination                                      | Therapeutic category | Observations                                                                 | Refs |
|-------------------------------------------------------|----------------------|------------------------------------------------------------------------------|------|
| Flufenamic Acid with ethenazamide                     | NSAIDs               | Increased solubility                                                          | [55] |
| Piroxicam with clonixin                               | NSAIDs               | Enhanced hydration stability                                                  | [27] |
| Tramadol with celecoxib                               | NSAIDs               | Optimized solubility and IDR, improved Cmax and bioavailability of celecoxib | [20] |
| Aceclofenac and paracetamol                           | NSAIDs               | Increased dissolution rate                                                    | [56] |
| Tenoxicam with salicylic acid                         | NSAIDs               | Increased IDR                                                                 | [57] |
| Piroxicam with salicylic acid                         | NSAIDs               | Pharmaceutical properties not evaluated                                        | [58] |
| Meloxicam with aspirin                                | NSAIDs               | 44-fold increase in pH 7.4 phosphate, buffer solubility along with improved   | [23] |
| Metacemol with levofloxacin                           | NSAIDs and antibacterial | Reduced hygroscopicity and improved photostability of levofloxacin            | [59] |
| Ibuprofen with levetiracetam                          | NSAIDs and antiepileptic | Chiral resolution                                                              | [60] |
| Carbamazepine with indomethacin                       | Antiasthmatic and NSAIDs | Pharmaceutical properties not evaluated                                        | [61] |
| Celecoxib with nicotinamide                           | NSAID and skin restorative | Pharmaceutical properties not evaluated                                        | [62] |
| Acmemetacin with nicotinamide                         | NSAID and skin restorative | Increased solubility                                                          | [63] |
| Indomethacin with nicotinamide                        | NSAID and skin restorative | Pharmaceutical properties not evaluated                                        | [64–65] |
| Naproxen with nicotinamide                            | NSAID and skin restorative | Increased IDR                                                                 | [66] |
| Flufenicam acid, niflumic acid, tolenamic acid, and mfenamic acid with nicotinamide | NSAIDs and skin restorative | Pharmaceutical properties not evaluated                                        | [67] |
| Aspirin with theophylline                             | NSAID and Antiasthmatic | Pharmaceutical properties not evaluated                                        | [68] |
| Flufenicam Acid with theophylline                     | NSAID and Antiasthmatic | Increased solubility and enhanced hygroscopic stability                        | [28,69] |
| Diflunisal and diclofenac with theophylline           | NSAID and Antiasthmatic | Increased solubility                                                          | [28] |
| Carbamazepine with aspirin                            | Antiepileptic and NSAIDs | Pharmaceutical properties not evaluated                                        | [70] |
| Apremilast with aspirin                               | Antipsoriatic and NSAIDs | Pharmaceutical properties not evaluated                                        | [71] |
| Theophylline with aspirin                             | Antiastrmatic and NSAIDs | Pharmaceutical properties not evaluated                                        | [68] |
| Sildenafil with aspirin                                | Erectile dysfunction and NSAIDs | Enhanced IDR                                                                 | [25] |
| Ethionamide with salicylic acid                       | Antitubercular and NSAIDs | Increased dissolution rate                                                    | [29] |
| Trosplum chloride with salicylic acid                 | Antispasmodic and NSAIDs | Pharmaceutical properties not evaluated                                        | [72] |
| Andrographolide with salicylic acid                   | Antiviral and NSAIDs | Increased solubility, faster dissolution rate, higher drug release, inhibited the chemical transformation of andrographolide to its inactive sulfate metabolite | [26] |
| Nevirapine with salicylic acid                        | Antiretroviral and NSAIDs | Increased solubility and dissolution rate                                      | [73] |
improved permeability (1.8 fold) compared to those of pure hydrochlorothiazide.

2.4. DDCs of the other APIs

Except for these DDCs discussed above, other 16 DDCs reported in the last decade are listed in Table 4. The pharmaceutical properties of 7 DDCs had not been evaluated. Among the other 9 DDCs, 8 DDCs presented improved dissolution properties and 2 DDCs showed enhanced stability. Sathyanarayana et al. reported a DDC formed with zoledronic acid and nicotinamide and this DDC presented a 20 fold increased solubility than zoledronic acid [33]. Nangia et al. reported a DDC comprising febuxostat and nicotinamide
Scheme 3 – The molecular structures of the APIs that formed the DDCs of diuretic drugs.

Scheme 4 – The molecular structures of the APIs that formed the other DDCs.

Table 2 – DDCs of antitubercular reported in the last decade.

| Drug combination                  | Therapeutic category | Observations                                                                 | Refs |
|-----------------------------------|----------------------|------------------------------------------------------------------------------|------|
| 4-aminosalicylic acid with isoniazid | Antitubercular       | Pharmaceutical properties not evaluated                                      | [74] |
| Pyrazinamide with isoniazid       | Antitubercular       | Drug-bridge-drug, optimized formulation capacity and in vitro/vivo synergistic effects | [31] |
| Isoniazid with 5-fluorocytosine   | Antitubercular and antineoplastic | Enhanced hydration stability                                                 | [30] |
| Isoniazid with entacapone         | Antitubercular and antiparkinsonian | Improved solubility and diffusion permeability                               | [36] |
| Isoniazid with hydrochlorothiazide | Antitubercular and diuretic, | Optimizing solubility and membrane diffusivity                              | [75] |
| Isoniazid with furosemide         | Antitubercular and skin restorative | Solubility and diffusion variations                                          | [76] |
| 4-Aminosalicylic acid with nicotinamide | Antitubercular | Pharmaceutical properties not evaluated                                      | [77] |
| Ethionamide with salicylic acid   | Antitubercular and NSAIDs | Increased dissolution rate                                                   | [29] |
| Entacapone with pyrazinamide      | Antiparkinsonian, and antitubercular | Improved solubility and diffusion permeability                              | [36] |
| Carbamazepine with 4-aminosalicylic acid | Antiepileptic and antitubercular | Increased solubility                                                         | [78] |
| Hydrochlorothiazide with pyrazinamide | Diuretic, and antitubercular | Enhanced IDR                                                                | [79] |
| Temozolomide with pyrazinamide    | Anticancer and antitubercular | Pharmaceutical properties not evaluated                                      | [80] |
| Isoniazid with nicotinamide       | Antitubercular and skin restorative | Comparable solubility and IDR                                               | [81] |
that had an enhanced IDR [34]. Dissolution rates were found to be 36.6 times faster for Febuxostat- nicotinamide DDC when compared to that of pure febuxostat. Sarma et al. developed a DDC of famotidine with theophyllinenbgh and such DDC improved the phase stability of famotidine at low pH [35]. In addition, some DDCs also showed improved diffusion/permeability. Nangia et al. reported a DDC synthesized by theophylline with antiparkinsonian agent entacapone [36]. This DDC presented 1.41 times higher solubility and 1.71 times faster IDR compared to pure entacapone. Diffusion rates in a Franz cell showed that the stable and high solubility DDC also has good permeability.

2.5. **Commercially available DDCs**

Entresto is the most recently marketed DDC drug that developed by Novartis in 2015. It is synthesized by the angiotensin receptor inhibitor valsartan with a neprilysin inhibitor prodrug (sacubitril) [37]. The combination of sacubitril plus valsartan inhibits neprilysin (neutral endopeptidase) via the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1) receptor via valsartan [38]. This DDC is a classic example of how cocrystals can influence pharmacokinetics. It improves the bioavailability of valsartan, and achieves the same therapeutic effect with a lower dose.

Dimenhydrinate is another marketed DDC that widely used for the prevention of motion sickness, including nausea and vomiting [39]. It is combined by diphenhydramine and 8-chlorotheophylline. Diphenhydramine is an antihistamine with anticholinergic and sedative effects and it mainly performs the antiemetic effect in this drug. However, it has a side effect of drowsiness and the stimulant 8-chlorotheophylline overcomes this drawback. Sodium

| Drug combination                        | Therapeutic category              | Observations                           | Refs |
|-----------------------------------------|-----------------------------------|----------------------------------------|------|
| Spironolactone with griseofulvin       | Diuretic and antifungal           | Pharmaceutical properties not evaluated| [82] |
| Chlorothiazide with carbamazepine      | Diuretic and antiepileptic        | Increased solubility                   | [83] |
| Hydrochlorothiazide with nicotinamide   | Diuretic and skin restorative     | Improved solubility and diffusion/ permeability | [32,84] |
| Acetazolamide with theophylline         | Diuretic and bronchodilator       | Pharmaceutical properties not evaluated| [85] |
| Furosemide with nicotinamide            | Diuretic and skin restorative     | Pharmaceutical properties not evaluated| [86-87] |
| Hydrochlorothiazide with pyrazinamide   | Diuretic, and antitubercular       | Enhanced IDR                           | [79] |
| Furosemide with theophylline            | Diuretic and bronchodilator       | Solubility and diffusion variations    | [76] |
| Hydrochlorothiazide with isoniazid      | Diuretic and antitubercular       | Optimizing solubility and membrane diffusivity | [75] |
| Furosemide with isoniazid              | Diuretic and antitubercular       | Solubility and diffusion variations    | [76] |

| Drug combination                        | Therapeutic category              | Observations                           | Refs |
|-----------------------------------------|-----------------------------------|----------------------------------------|------|
| 5-Fluorocytosine with 5-fluorouracil    | Antineoplastic                    | Pharmaceutical properties not evaluated| [88] |
| Sulfathiazole with sulfanilamide        | Antibacterial                     | Pharmaceutical properties not evaluated| [44] |
| Lamotrigine with phenobarbital          | Anticonvulsants                   | Suppressed solubility and IDR          | [89] |
| Telmisartan with atenolol               | Anti-hypertension                 | Improved IDR                           | [90] |
| Dapsone with sulfanilamide             | Antileptotic, and antibacterial   | Increased solubility                   | [91] |
| Pyrimethamine with carbamazepine        | Antimalarial, and antiepileptic   | Pharmaceutical properties not evaluated| [92] |
| Zoledronic acid with nicotinamide       | anti-resorptive and skin restorative | Increased solubility                   | [33] |
| Tegafur with nicotinamide               | Anti-cancer and skin restorative  | Increased solubility and IDR           | [93] |
| Olanzapine with nicotinamide            | Neuroleptics and skin restorative | Pharmaceutical properties not evaluated| [94] |
| Temozolomide with nicotinamide          | Anti-cancer and skin restorative  | Pharmaceutical properties not evaluated| [80] |
| Febuxostat with nicotinamide            | Gout suppressants and skin restorative | Increased IDR                           | [34] |
| Tranilast with nicotinamide             | Antiallergic and skin restorative | Improved solubility and photostability | [24] |
| Fatomidine with theophylline            | histamine-2 blocker and bronchodilator | Enhanced stability at low pH         | [35] |
| Sulfathiazole with theophylline          | Antibacterial and bronchodilator  | Pharmaceutical properties not evaluated| [44] |
| Entacapone with theophylline            | Antiparkinsonian and bronchodilator | Improved solubility and diffusion permeability | [36] |
| Pyrimethamine with theophyllinenbgh     | Antimalarial and bronchodilator   | Pharmaceutical properties not evaluated| [92] |

| Drug          | Components                           | Indication   |
|---------------|--------------------------------------|--------------|
| Depakote      | Valproic acid and valproate sodium   | Epilepsy     |
| Entresto      | Valsartan sodium and sacubitril sodium | Heart failure |
| Dimenhydrinate| Diphenhydramine and 8-chlorotheophylline | Motion sickness |
| Dichloralphenazone | Antipyrin and hypnotic chloral hydrate | Vascular headaches |
valproate is the other DDC and it is crystallized by sodium valproate with its free acid valproic acid [40]. Muscle relaxant dichlorphenazone is a DDC combined with NSAID antipyrin and hypnotic chloral hydrate that used for the treatment of tension and vascular headaches [41].

3. Synthesis, characterization, and evaluation of DDC

Generally, the preparation methods of DDCs are similar to the conventional methods used in the preparation of other common co-crystals (Fig. 1). Solvent evaporation, cooling, slurrying, anti-solvent, grinding and liquid-assisted grinding are the common techniques that have been used for the preparation of DDC. Rohani and Lu synthesized the DDC of sulfamethazine-theophylline using slow evaporation, neat grinding and solvent-drop grinding methods, respectively [42]. Nehm et al. obtained a DDC of carbamazepine-nicotinamide by slurrying [43]. Lee et al. prepared two DDCs of sulfathiazole–theophylline, and sulfathiazole–sulfanilamide by cooling experiments [44].

The characterization methods of DDCs are also the same to that of the common co-crystals (Fig. 2), including microscope, single crystal x-ray diffraction (SCXRD), powder x-ray diffraction (PXRD), solid state nuclear magnetic (SSNMR), infrared spectroscopy (IR), raman spectroscopy, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and dynamic vapor sorption (DVS) etc. [45]. The evaluated properties of the reported DDCs in the last decade discussed above are presented in Fig. 3. Among the 63 reported DDCs, 26 of them did not evaluate their pharmaceutical properties, 32 DDCs determined the solubility or/dissolution rate, 7 DDCs investigated their permeability and 6 DDCs studied their physical or chemical stability. In addition, 1 DDC optimized formulation capacity and another 3 DDCs improved the bioavailability.

4. Opportunities and challenges

Recent estimates show that the cost of developing a new drug is about US$2.8 billion [46]. Furthermore, the number of approved drugs per billion of spending has halved each year since the 1950s. Here, DDCs offer a low risk, low-cost, but high reward route to new and better medicines. It could improve the physicochemical and biopharmaceutical properties of a medicine by addition of a suitable drug co-former without any chemical modification. DDCs could overcome the disadvantages of FDCs, and treat additional indications by drug-drug interactions with modulated physicochemical properties of each API. In terms of regulation, the FDA firstly published guidance on the regulatory classification of co-crystals in 2013 and released the final version of the Guidance in February 2018 [47]. In Europe, the European Medicines Agency (EMA) released a reflective document in 2015 that classified coocrystals in a similar way to the salts of APIs [48]. It is expected that the FDA and EMA guidelines would support the growth of a DDC market. In addition, a DDC could obtain a new patent which could mean longer even new exclusivity and would enhance the existing commercial value of a product in the pharmaceutical industry.

However, there are many challenges for the development of DDC. One of the major challenges is the designing and synthesizing of DDCs. From the DDCs discussed above, it could be found that most of the DDCs reported were primarily focused on identifying hydrogen-bonding patterns, understanding the role of supramolecular interactions. The obtained DDCs always designed from molecular structure and prepared by high throughput cocrystal screening. It could not be guaranteed that the synthesized DDC is a
5. **Future prospects**

From the reported DDCs discussed above, it was observed that although thousands of pharmaceutical cocrystals had been reported, drug–drug cocrystals are scarce. The reason may be that the selection of appropriate drug combination for development is challenging, with multiple factors to consider, including, differential solubility, molecular interaction, packing patterns, dosage compatibility, therapeutic applications and drug–drug interactions. In addition, the marketed APIs are numbered, and the suitable drug–drug combinations are limited. To overcome these disadvantages, we can make efforts from three aspects. Firstly, co-crystallization technique selection is the most important as the nature, properties and morphology of co-crystals formed were influenced by this process. Choosing suitable cocrystal methods and develop more effective screening procedures may increase the success rate of the DDCs preparation. Secondly, two different compounds always could form more than one cocrystals with different stoichiometric ratio. Exploring DDCs with different stoichiometric ratios could be used to overcome the dosage problem. Thirdly, extend the DDCs to drug–nutraceuticals cocrystals could be advantageous and relatively easier to develop. Numerous clinical trials confirmed the potential benefits of various nutraceuticals in multiple disorders [51–53]. However, most nutraceuticals are weakly ionizing compounds that display poor solubility and bioavailability [54]. The clinical applications of nutraceuticals are limited by their low bioavailability. Soluble drugs could improve the absorption of these nutraceuticals and the nutraceuticals could modulate some physicochemical properties and provide drug–drug synergism for marketed APIs. This could lead to the emergence of an entirely new range of safe and effective therapeutic combinations of APIs and nutraceuticals with synergistic benefits and reduced adverse effects.

6. **Conclusion**

DDC has attracted the attentions of many scientists for several years by its low risk, low-cost and other advantages. However, to date, there is limited published work available on DDCs and the marketed DDCs are rare. The development of DDCs has many challenges. There is a need for pharmaceutical scientists to develop robust models for predicting DDC formation, to give useful insights into the relevance of supramolecular interactions and their molecular patterns, and to provide mechanistic understanding of the association and dissociation patterns of DDCs. We could invent new suitable cocrystallization technology, develop more effective screening program and extend DDCs to drug-nutraceuticals cocrystals to overcome the challenges of DDC development. As a result, it may bring about a new opportunity for drug-drug combination and new applications of the conventional drug.

**Conflict of interest**

The authors declare that there is no conflict of interest. The authors alone are responsible for the content and writing of this article.

**Supplementary materials**

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ajps.2020.06.004.

**REFERENCES**

[1] van Hasselt JGC, Iyengar R. Systems pharmacology: defining the interactions of drug combinations. Annu Rev Pharmacol Toxicol 2019;59:21–40.

[2] Vakil V, Trappe W. Drug combinations: mathematical modeling and networking methods. Pharmaceutics 2019;11(5):1–31.

[3] Chang SY, Sun CC. Interfacial bonding in formulated bilayer tablets. Eur J Pharm Biopharm 2020;147:69–75.

[4] Hwang KM, Nguyen TT, Seok SH, Jo HI, Cho CH, HWang KM, et al. Swellable and porous bilayer tablet for gastroretentive drug delivery: preparation and in vitro-in vivo evaluation. Int J Pharm 2019;572:118783.

[5] Thipparaboina R, Kumar D, Chavan RB, Shastri NR. Multidrug co-crystals: towards the development of effective therapeutic hybrids. Drug Discov Today 2016;21(3):481–90.

[6] Simon F. The trouble with making combination drugs. Nature Rev Drug Discov 2006;5(11):881–2.

[7] Baranwal Y, Reman-Ospina AD, Keyvan G, Ha JM, Hong EP, Muzzio FJ, et al. Prediction of dissolution profiles by non-destructive NIR spectroscopy in bilayer tablets. Int J Pharm 2019;565:419–36.
[8] Aitipamula S, Banerjee R, Bansal AK, Biradha K, Chenev ML, Choudhury AR, et al. Polymorphs, salts, and cocrystals: what's in a name? Cryst Growth Des 2012;12(5):2147–52.

[9] Dipti S, Zeeshan F, Chanchal Deep K. Multicomponent pharmaceutical cocrystals: a novel approach for combination therapy. Mini-Rev Med Chem 2018;18(14):1160–7.

[10] Walsh RD, Bradner MW, Fleischman S, Morales LA, Moulton B, Rodriguez-Hornedo N, et al. Crystal engineering of the composition of pharmaceutical phases. Chem Commun 2003;39(2):186–7.

[11] Kuminek G, Cavanagh KL, da Piedade MFM, Rodriguez-Hornedo N. Posaconazole cocrystal with superior solubility and dissolution behavior. Cryst Growth Des 2019;19(11):6592–602.

[12] Eedara BB, Tucker IG, Zujovic ZD, Rades T, Price JR, Das SC. Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs. Eur J Pharm Sci 2019;136:1–11.

[13] Li JM, Dai XL, Li GJ, Lu TB, Chen JM. Constructing anti-glioma drug combination with optimized properties through cocrystallization. Cryst Growth Des 2018;18(8):4270–4.

[14] Yu QH, Yan ZC, Bao JJ, Wang JR, Mei XF. Taming photo-induced oxidative degradation of dihydropropyridine drugs through cocrystallization. Chem Commun 2017;53(91):12266–9.

[15] Tahara A, Kurosaki E, Yokono M, Yamajuku K, Kihara R, Hayashizaki Y, et al. Pharmacological profile of irapigulifloxin (asp1941), a novel selective sglt2 inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 2012;385(4):423–36.

[16] Bowles P, Brenke SJ, Caron S, Do NM, Drexler MT, Duan S, et al. Commercial route research and development for sglt2 inhibitor candidate etruliflinox. Org Process Res Dev 2014;18(1):66–81.

[17] Harrison WTA, Yathirajan HS, Bindya S, Anilkumar HG, Devaraju. Esicalopram oxalate: co-existence of oxalate dianions and oxalic acid molecules in the same crystal. Acta Crystallogr. C 2007;63(Pt 2):o129–31.

[18] O’ Nolan D, Perry ML, Zaworotko MJ. Chloral hydrate polymorphs and cocrystal revisited: solving two pharmaceutical cold cases. Cryst Growth Des 2016;16(4):2211–17.

[19] Sekhon BS. Drug-drug co-crystals. DARU 2012;20(1):45.

[20] Almansa C, Mercé R, Tesson N, Farran J, Tomás J, Plata-Salaman CR. Co-crystal of tramadol hydrochloride-celecoxib (cct): a novel api–api co-crystal for the treatment of pain. Cryst Growth Des 2017;17(4):1884–92.

[21] Gascon N, Almansa C, Merlos M, Miguel Vela J, Encina G, Morte A, et al. Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic. Expert Opin Inv Drug. 2019;28(5):399–409.

[22] López-Cedrún J, Videla S, Burgueño M, Juárez I, Aboul-Hosn S, Martin-Granizo R, et al. Co-crystal of tramadol-celecoxib in patients with moderate to severe acute post-surgical oral pain: a dose-finding, randomised, double-blind, placebo- and active-controlled, multicentre, phase ii trial. Drugs R D 2018;18(2):137–48.

[23] Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam-anesthetic cocrystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci 2011;100(6):2172–81.

[24] Geng N, Chen JM, Li ZJ, Jiang L, Lu TB. Approach of cococrystallization to improve the solubility and photostability of tranilast. Cryst Growth Des 2013;13(8):5346–53.

[25] Žegarac M, Lekšić E, Šket P, Plavec J, Devčić Bogdanović M, Bučar DK, et al. A sildenafil cocrystal based on acetylsalicylic acid exhibits an enhanced intrinsic dissolution rate. CrystEngComm 2014;16(1):32–5.

[26] Suresh K, Goud NR, Nangia A. Androgapholide: solving chemical instability and poor solubility by means of cocrystals. Chem – Asian. J. 2013;8(12):3032–41.

[27] Li DX, Li J, Deng ZW, Zhang HL. Piroxicam-clonixin drug-drug cocrystal solvates with enhanced hydration stability. CrystEngcomm 2019;21(28):4145–9.

[28] Surov AO, Voronin AP, Manin AN, Manin NG, Kuzmina LG, Churakov AV, et al. Pharmaceutical cocrystals of difunisal and diclofenac with theophylline. Mol Pharm 2014;11(10):3707–15.

[29] Bencosme D, Bordignon S, Rossi F, Priola E, Nervi C, Godetto R, et al. Selective synthesis of a salt and a cocrystal of the ethionamide-salicylic acid system. Cryst Growth Des 2020;20(2):906–15.

[30] Souza MS, Diniz LF, Vogt L, Carvalho Jr PS, D’vries RF, Ellena J. Mechanochemical synthesis of a multicomponent solid form: the case of 5-fluorocytosine isoniazid codrug. Cryst Growth Des 2018;18(9):5202–9.

[31] Liu F, Song Y, Liu YN, Li YT, Wu ZY, Yan CW. Drug-drug-drug ternary cocrystallization strategy for antituberculosis drugs combination. Cryst Growth Des 2018;18(3):1283–6.

[32] Sanphui P, Devi VK, Clara D, Malviya N, Ganguly S, Desiraju GR. Cocrystals of hydrochlorothiazide-salicylic acid and diffusion/permeability enhancements through drug-coformer interactions. Mol Pharm 2015;12(5):1615–22.

[33] Varma A, Laxmi P, Pai A, Pai G, Vasantharaju SG, Sathyarayana MB. Designing of stable co-crystals of zoledronic acid using suitable coformers. Chem Pharm Bull (Tokyo) 2019;67(8):816–23.

[34] Maddileti D, Jayabun SK, Nangia A. Soluble cocrystals of the xanthine oxidase inhibitor febuxostat. Cryst Growth Des 2013;13(7):3188–96.

[35] Saikia B, Sultana N, Kaushik T, Sarma B. Engineering a remedy to improve phase stability of famotidine under physiological ph environments. Cryst Growth Des 2019;19(11):6472–81.

[36] Bommaka MK, Manavana MKC, Suresh K, Gunnam A, Nangia A. Entacapone: improving aqueous solubility, diffusion permeability, and cocrystal stability with theophylline. Cryst Growth Des 2018;18(10):6061–9.

[37] Khaili F, Kabbach G, Said S, Mukherjee D. Entresto, a new panacea for heart failure? Cardiovasc Hematol Agents Med Chem 2018;16(1):5–11.

[38] Entresto Fala L. (sacubitril/valsartan): first-in-class angiotensin receptor neprilysin inhibitor fda approved for patients with heart failure. Am Health Drug Benefits 2015;8(6):330–4.

[39] Putra OD, Yoshida T, Umeda D, Higashi K, Uekusa H, Yonemochi E. Crystal structure determination of dimenhydrinate after more than 60 years: solving salt-cocrystal ambiguity via solid-state characterizations and solubility study. Cryst Growth Des 2016;16(9):5223–9.

[40] Petrovičevski G, Naumov P, Jovanovski G, N. SW. Unprecedented sodium–oxygen clusters in the solid-state structure of trisodium hydrogenetavralproate monohydrate: a model for the physiological activity of the anticonvulsant drug epilim®. Inorg Chem Commun 2008;11(1):81–4.

[41] Clark S, Dichloralphenazona. In: Enna SJ, Bylund SB, editors. xPharm: The Comprehensive Pharmacology Reference. New York: Elsevier; 2007. p. 1–2.

[42] Lu JIE, Rohani S. Synthesis and preliminary characterization of sulfamethazine-theophylline co-crystal. J Pharm Sci 2010;99(9):4042–7.
Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst Growth Des 2006;6(2):592–600.

Yeh KL, Lee T. Intensified crystallization processes for 1:1 drug–drug cocrystals of sulfathiazole–theophylline, and sulfathiazole–sulfanilamide. Cryst Growth Des 2018;18(3):1339–49.

Vemuri VD, Lankalapalli S. Insight into concept and progress on pharmaceutical co-crystals: an overview. Indian J Pharm Educ 2019;53(4):5522–38.

DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of r&d costs. J Health Econ 2016;47:20–33.

FDA. Guidance for industry – regulatory classification of pharmaceutical co-crystals. 2018.

EMA. Reflection paper on the use of cocrystals of active substances in medicinal products. 2015.

Nakao S, Fuji S, Sakaki T, Tomita K. The crystal and molecular structure of the 2:1 molecular complex of theophylline with phenobarbital. Acta Crystallogr B 1977;33(5):1373–8.

Bhatt PM, Azim Y, Thakur TS, Desiraju GR. Co-crystals of the anti-hiv drugs lamivudine and zidovudine. Cryst Growth Des 2009;9(2):951–7.

Dilip Gosh D.B., Tetsuya K. Clinical aspects of functional foods and nutraceuticals. CRC Press: 2014.

Saklani A, Kuttu SK. Plant-derived compounds in clinical trials. Drug Discov Today 2008;13(3):161–71.

Andrew R, Izzo AA. Principles of pharmacological research of nutraceuticals. Br J Pharmcol 2017;174(11):1177–94.

Sinha AS, Maguire AR, Lawrence SE. Cocrytallization of nutraceuticals. Cryst Growth Des 2015;15(2):984 09.

Nechipadappu SK, Tekuri V, Trivedi DR. Pharmaceutical co-crystal of flufenamic acid: synthesis and characterization of two novel drug–drug co-crystal. J Pharm Sci 2017;106(5):1384–90.

Narendra CVG, Adityanath P, Somesh S, Sheetal C. Co-crytallization of aceclofenac and paracetamol and their characterization. Int J Pharm Life Sci 2011;2(8):1020–8.

Bolla G, Sanphui P, Nagia A. Solubility advantage of tenoxicam phenolic cocrystals compared to salts. Cryst Growth Des 2013;13(5):1988–2003.

Wales C, Thomas LH, Wilson CC. Tautomerisation and polymorphism in molecular complexes of piroxicam with mono-substituted benzoic acids. CrystEngComm 2012;14(21):7264–74.

Shinozaki T, Ono M, Higashi K, Moribe K. A novel drug–drug cocrystal of levofloxacin and metacetamol: reduced hygroscopicity and improved photostability of levofloxacin. J Pharm Sci 2019;108(7):2383–90.

Harmsen B, Leysens T. Dual-drug chiral resolution: enantiospecific cocrytallization of (S)-ibuprofen using levetiracetam. Cryst Growth Des 2018;18(1):441–8.

Majumder M, Buckton G, Rawlinson-Malone CF, Williams AC, Spellman MJ, Shankland N, et al. A carbamazepine-indomethacin (1:1) cocrystal produced by milling. CrystEngComm 2011;13(21):6327–8.

Zhang S-W, Brunskill APJ, Schwartz E, Sun S. Celecoxib–nicotinamide cocrystal revisited: can entropy control cocrystal formation? Cryst Growth Des 2017;17(5):2836–43.

Sanphui P, Bolla G, Nagia A, Chernyshev V. Acemetacin cocrystals and salts: structure solution from powder x-ray data and form selection of the pipazine salt. IUCrJ 2014;12(2):136–50.

Majumder M, Buckton G, Rawlinson-Malone CF, Williams AC, Spellman MJ, Pidcock E, et al. Application of hydrogen-bond propensity calculations to an indomethacin–nicotinamide (1:1) co-crystal. CrystEngComm 2013;15(20):4041–4.

Dudenko DV, Williams PA, Hughes CE, Antzutkin ON, Velaga SP, Brown SP, et al. Exploiting the synergy of powder x-ray diffraction and solid-state nmr spectroscopy in structure determination of organic molecular solids. J Phys Chem C 2013;117(23):12258–65.

Ando S, Kikuchi J, Fujimura Y, Ida Y, Higashi K, Moribe K, et al. Physicochemical characterization and structural evaluation of a specific 2:1 cocrystal of naproxen–nicotinamide. J Pharm Sci 2012;101(9):3214–21.

Fábián L, Hamill N, Eccles KS, Moynihan HA, Maguire AR, McCausland L, et al. Cocrystals of fenamic acids with nicotinamide. Cryst Growth Des 2011;11(8):3522–8.

Darwisah S, Zeiglinski J, Krishna GR, Shaikh R, Khraisheh M, Walker GM, et al. A new 1:1 drug–drug cocrystal of theophylline and aspirin: discovery, characterization, and construction of ternary phase diagrams. Cryst Growth Des 2018;18(12):7526–32.

Guo M, Wang K, Hamill N, Lorimer K, Li M. Investigating the influence of polymers on supersaturated fenameric acid cocrystal solutions. Mol Pharm 2016;13(9):3292–307.

Nicolaï B, Fournier B, Dahhoui S, Gillet JM, Ghermani NE. Crystal and electron properties of carbamazepine–aspirin co-crystal. Cryst Growth Des 2019;19(2):1308–21.

Wang FY, Zhang Q, Zhang Z, Gong X, Wang JR, Mei X. Solid-state characterization and solubility enhancement of apremilast drug–drug cocrystals. CrystEngComm 2018;20(39):5945–8.

Sládková V, Cibulková J, Vignar, Šturc A, Kratochvíl B, Rohlické J. Application and comparison of cocrytallization techniques on troposium chloride cocrystals. Cryst Growth Des 2014;14(6):2931–6.

Caira MR, Bourne SA, Sam sodien H, Engel E, Liebenberg W, Stieger N, et al. Co-crystals of the antiretroviral nevirapine: crystal structures, thermal analysis and dissolution behaviour. CrystEngComm 2012;14(7):2541–51.

Grobelny P, Mukherjee A, Desiraju GR. Drug–drug co-crystals: temperature-dependent proton mobility in the molecular complex of isoniazid with 4-amino salicylic acid. CrystEngComm 2011;13(12):4538–64.

Gopi SP, Banik M, Desiraju GR. New cocrystals of hydrochlorothiazide: optimizing solubility and membrane diffusivity. Cryst Growth Des 2017;17(1):308–16.

Banik M, Gopi SP, Ganguly S, Desiraju GR. Cocrystal and salt forms of furosemide: solubility and diffusion variations. Cryst Growth Des 2016;16(9):5418–28.

Sarcevic I, Orola L, Belyakov S, Viedis MV. Spontaneous cocrystal hydrate formation in the solid state: crystal structure aspects and kinetics. New J Chem 2013;37(10):2978–82.

Drozd KV, Manin AN, Churakov AP, Perlovich GL. Novel drug–drug cocrystals of carbamazepine with para-amino salicylic acid: screening, crystal structures and comparative study of carbamazepine cocrystal formation thermodynamics. CrystEngComm 2017;19(30):4273–86.

Wang JR, Ye C, Mei X. Structural and physicochemical aspects of hydrochlorothiazide co-crystals. CrystEngComm 2014;16(30):6996–7003.

Sanphui P, Babu N, Nagia A. Temozolomide cocrystals with carboxamide coformers. Cryst Growth Des 2013;13(5):2208–19.

Aitipamula S, Wong ABH, Chow PS, Tan RBH. Novel solid forms of the anti-tuberculosis drug, isoniazid: ternary and polymorphic cocrystals. CrystEngComm 2013;15(29):5877–87.

Grecu T, Prohens R, McCabe JF, Carrington EJ, Wright JS, Brammer L, et al. Cocrystals of spironolactone and griseofulvin based on an in silico screening method. Cryst Eng Comm 2017;19(26):3592–9.
[83] Aljohani M, Pallipurath AR, McArdle P, Erxleben A. A comprehensive cocrystal screening study of chlorothiazide. Cryst Growth Des 2017;17(10):5223–32.

[84] Sanphui P, Rajput L. Tuning solubility and stability of hydrochlorothiazide co-crystals. Acta. Crystallogr. B 2014;70(1):81–90.

[85] Kakkar S, Bhattacharya B, Reddy CM, Ghosh S. Tuning mechanical behaviour by controlling the structure of a series of theophylline co-crystals. CrystEngComm 2018;20(8):1101–9.

[86] Harriss BI, Vella-Zarb L, Wilson C, Evans IR. Furosemide cocrystals: structures, hydrogen bonding, and implications for properties. Cryst Growth Des 2014;14(2):783–91.

[87] Ueto T, Takata N, Muroyama N, Nedu A, Sasaki A, Tanida S, et al. Polymorphs and a hydrate of furosemide-nicotinamide 1:1 cocrystal. Cryst Growth Des 2012;12(1):485–94.

[88] da Silva CCP, de Melo CC, Souza MS, Diniz LF, Carneiro RL, Ellena J. 5-fluorocytosine/5-fluourouracil drug-drug cocrystal: a new development route based on mechanochemical synthesis. J Pharm Innov 2019;14(1):50–6.

[89] Kaur R, Cavanagh KL, Rodríguez-Hornedo N, Matzger AJ. Multidrug cocrystal of anticonvulsants: influence of strong intermolecular interactions on physicochemical properties. Cryst Growth Des 2017;17(10):5012–16.

[90] Haneef J, Chadha R. Drug-drug multicomponent solid forms: cocrystal, coamorphous and eutectic of three poorly soluble antihypertensive drugs using mechanochemical approach. AAPS PharmSciTech 2017;18(6):2279–90.

[91] Jiang L, Huang Y, Zhang Q, He H, Xu Y, Mei X. Preparation and solid-state characterization of dapsone drug–drug co-crystals. Cryst Growth Des 2014;14(9):4562–73.

[92] Delori A, Galek PTA, Pidcock E, Patni M, Jones W. Knowledge-based hydrogen bond prediction and the synthesis of salts and cocrystals of the anti-malarial drug pyrimethamine with various drug and gras molecules. CrystEngComm 2013;15(15):2916–28.

[93] Aitipamula S, Chow PS, Tan RBH. Crystal engineering of tegafur cocrystals: structural analysis and physicochemical properties. Cryst Growth Des 2014;14(12):6557–69.

[94] Clarke HD, Hickey MB, Mouton B, Perman JA, Peterson ML, Wojtas Ł, et al. Crystal engineering of isostructural quaternary multicomponent crystal forms of olanzapine. Cryst Growth Des 2012;12(8):4194–201.